Benefits
Traditional use as a soothing tea for the mouth and throat
European regulators register ribwort plantain leaf as a traditional herbal medicine, used as a demulcent for mouth or throat irritation with an associated dry cough and for cough during a cold. That status rests on at least 30 years of documented use, not on trial results: the assessors declined the higher evidence tier because controlled clinical studies of the leaf have not been performed.
Demulcent mucilage for throat comfort
The dried leaf contains roughly 2 to 6.5 percent mucilage, water-binding sugars that are not absorbed and are thought to lay a protective film over irritated mucous membranes. In a tissue test on pig cheek lining, plantain polysaccharides adhered only moderately, less than calendula or bladderwrack. A coating effect on the throat is plausible, but nobody has measured it in people.
Post-marketing syrup study with no placebo group
In a post-marketing study of an alcohol-based plantain syrup, summarized by the EU herbal committee, 593 people, mostly with acute respiratory infections, acute bronchitis or irritative cough after an infection, rated cough intensity about 67 percent lower after 3 to 14 days. There was no comparison group, and the EU assessors judged that this design gives the result no clinical relevance, so the change cannot be credited to the herb.
An ingredient in two multi-herb honey syrups tested in children
Two small placebo-controlled trials in children tested honey syrups that combine plantain with other herbs. A four-herb syrup in ages 5 to 11 lowered daytime scores versus placebo from day 3 and night scores from day 4; a three-herb syrup in ages 3 to 6 differed from placebo overall only on night scores at day 4. Companies sponsored or supplied both, and neither can isolate plantain. EU guidance advises against oral use under age 3.
Muscle-relaxing and anti-inflammatory activity in lab and animal studies
In tissue-bath work the extract relaxed guinea pig windpipe and gut muscle, with luteolin and acteoside among the active constituents. In a cell-free test it partly inhibited the inflammatory enzyme COX-2, and an oral extract trimmed rat paw swelling by about 11 percent. EU assessors noted the concentrations were high and that clinical relevance cannot be estimated. None of this has been tested in people.
Mechanism of action
Mucilage film on the mucous membranes
Plantain mucilage is built mainly from arabinose and galactose-rich polysaccharides that swell with water, are not absorbed, and are thought to cover the mucosa with a protective layer against local irritation. That physical film, rather than any absorbed compound, is the proposed basis for the demulcent claim.
Antispasmodic phenolics: acteoside and luteolin
An ethanolic extract of the aerial parts inhibited contractions of isolated guinea pig ileum triggered by acetylcholine, histamine, potassium and barium, and also barium-induced tracheal contractions. Luteolin and acteoside relaxed tracheal tissue, whereas aucubin and catalpol did not relax the gut strip.
Anti-inflammatory activity in cell-free and animal models
A freeze-dried ethanol extract inhibited COX-2 by 37 to 58 percent at high concentrations in a cell-free assay while sparing 5-lipoxygenase, and an oral extract cut carrageenan paw swelling in rats by 11 percent. Isolated acteoside, plantamajoside and aucubin were anti-inflammatory in mouse models.
Iridoids aucubin and catalpol, with poor oral uptake
The leaf holds about 2 to 3 percent iridoid glycosides, up to 9 percent in young leaves, mainly aucubin and catalpol. In rats only about 19 percent of oral aucubin reached the circulation, and it breaks down within hours in stomach-strength acid. EU assessors could not name any constituent with known therapeutic activity.
Clinical trials
Pilot randomized, double-blind, placebo-controlled multicenter trial of Sediflù (Seditus), a eucalyptus honey syrup with dry extracts of plantain leaf, horehound flower, sundew and ivy leaf, given for dry or productive cough. Plantain is one of four extracts with no stated lead, so this is a blend result, not a plantain result (Núñez et al. 2024, Clin Pediatr (Phila))
56 children aged 5 to 11, 27 on the syrup and 29 on placebo, recruited at two primary care practices in Madrid; 10 ml twice daily for 7 days.
Against placebo, daytime scores were lower from day 3 and nighttime scores from day 4, both 71 percent lower by day 7 (P < .05). No adverse effects were recorded in either group. Cinfa Laboratories sponsored the trial (the syrup is made by Sakura Italia), and two authors had advised Cinfa. With four herbal extracts plus honey in one product, no share of the effect can be assigned to plantain.
Randomized, double-blind, placebo-controlled multicenter trial of Grintuss pediatric syrup, a medical device made from fractions of Grindelia robusta, Plantago lanceolata and Helichrysum italicum with honey, in children with cough lasting 7 days to 3 weeks. Grindelia is listed first and plantain is one of three plant fractions, so this is a blend result, not a plantain result (Canciani et al. 2014, Ital J Pediatr)
102 children aged 3 to 6, 51 per group (91 completed), at pediatric units in Udine and Pavia, Italy; 5 ml four times daily for 8 days.
Across all children, only the nighttime score at day 4 differed from placebo (p = 0.03); the other gains were within the syrup group. In a subgroup analysis of children with higher daytime scores at the start, 13 of 14 improved on the syrup versus 7 of 13 on placebo (p = 0.03). Adverse events occurred in 17 children in each arm, none judged related to the product. Aboca supplied the syrup and placebo, and one author had advised Aboca among other firms.